{"brief_title": "Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis", "brief_summary": "OBJECTIVES: I. Assess the safety and efficacy of olsalazine, a dimer of 5-aminosalicylic acid, in men with ankylosing spondylitis unresponsive to nonsteroidal anti-inflammatory drugs and physiotherapy.", "detailed_description": "PROTOCOL OUTLINE: Patients are treated with daily olsalazine. The dose is increased each week until the protocol dose is reached. Supplemental acetaminophen is allowed; nonsteroidal anti-inflammatory drugs continue unchanged. Concurrent sulfasalazine is prohibited.", "condition": "Ankylosing Spondylitis", "intervention_type": "Drug", "intervention_name": "olsalazine", "criteria": "PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Meets modified New York diagnostic criteria - Active disease, i.e., morning stiffness for more than 30 minutes - Failed or experienced nonlife-threatening reaction to prior sulfasalazine - No significant hematologic, hepatic, or renal disease", "gender": "Male", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "id": "NCT00004288.xml"}